Journal Watch · Frontiers in Immunology · 2026
Evaluation of a strain Long human respiratory syncytial virus with <i>M2-2</i> gene deletion in intranasally vaccinated BALB/c mice.
Furthermore, the vaccine conferred protection against subsequent RSV challenge with no signs of enhanced respiratory disease (ERD).<h4>Conclusion</h4>These results support the application of <i>M2-2</i> deletion strategy to the parental RSV strain Long backbone, providing a solid foundation for further evaluation and development of RSV LAVs.
TL;DR
Furthermore, the vaccine conferred protection against subsequent RSV challenge with no signs of enhanced respiratory disease (ERD).<h4>Conclusion</h4>These results support the application of <i>M2-2</i> deletion strategy to the parental RSV strain Long backbone, providing a solid foundation for further evaluation and development of RSV LAVs.
Key findings
- Following intranasal immunization, RLΔM2-2 robustly induced systemic and pulmonary humoral and cellular immune responses including preF-specific antibodies, neutralizing antibody responses, and RSV-specific CD8<sup>+</sup> T-cell responses characterized by a Th1-biased immune profile.
- Furthermore, the vaccine conferred protection against subsequent RSV challenge with no signs of enhanced respiratory disease (ERD).<h4>Conclusion</h4>These results support the application of <i>M2-2</i> deletion strategy to the parental RSV strain Long backbone, providing a solid foundation for further evaluation and development of RSV LAVs.
What they did
Subsequently, the <i>in vitro</i> and <i>in vivo</i> characteristics of these constructed recombinant RSV strains were evaluated.<h4>Results</h4>In HEp-2 and Vero cells, the recombinant strains RLΔM2-2 and RLΔM2-2112 displayed reduced replication capability compared with the parental <i>wt</i>RSV. In BALB/c mice, RLΔM2-2-infected groups demonstrated significantly lower lung viral loads and less pronounced body weight loss than those infected with RLΔM2-2112.
Full abstract (original)
Background: <h4>Background</h4>Human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI) worldwide, particularly in infants, the elderly and immunocompromised individuals. Despite this substantial disease burden, no licensed pediatric vaccines are currently available for infants aged ≥ 6 months, highlighting an urgent need for effective immunization strategies.<h4>Methods</h4>Live-attenuated vaccines (LAVs) were developed and characterized based on RSV subgroup A strain Long (<i>wt</i>RSV) by deleting the <i>M2-2</i> gene alone or by further introducing silent mutations into the small hydrophobic (<i>SH</i>) gene alongside a 112-nucleotide deletion within its downstream untranslated region.
What they did: Subsequently, the <i>in vitro</i> and <i>in vivo</i> characteristics of these constructed recombinant RSV strains were evaluated.<h4>Results</h4>In HEp-2 and Vero cells, the recombinant strains RLΔM2-2 and RLΔM2-2112 displayed reduced replication capability compared with the parental <i>wt</i>RSV. In BALB/c mice, RLΔM2-2-infected groups demonstrated significantly lower lung viral loads and less pronounced body weight loss than those infected with RLΔM2-2112.
Results & conclusions: Following intranasal immunization, RLΔM2-2 robustly induced systemic and pulmonary humoral and cellular immune responses including preF-specific antibodies, neutralizing antibody responses, and RSV-specific CD8<sup>+</sup> T-cell responses characterized by a Th1-biased immune profile. Furthermore, the vaccine conferred protection against subsequent RSV challenge with no signs of enhanced respiratory disease (ERD).<h4>Conclusion</h4>These results support the application of <i>M2-2</i> deletion strategy to the parental RSV strain Long backbone, providing a solid foundation for further evaluation and development of RSV LAVs.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1829916 · PubMed 42338594.
Why it matters for pharma & biotech
- Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: vaccines
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Furthermore, the vaccine conferred protection against subsequent RSV challenge with no signs of enhanced respiratory disease (ERD).<h4>Conclusion</h4>These results support the application of <i>M2-2</i> deletion strategy to the parental RSV strain Long backbone, providing a solid foundation for further evaluation and development of RSV LAVs.
What type of study is this?
It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. Subsequently, the <i>in vitro</i> and <i>in vivo</i> characteristics of these constructed recombinant RSV strains were evaluated.<h4>Results</h4>In HEp-2 and Vero cells, the recombinant strains RLΔM2-2 and RLΔM2-2112 displayed reduced replication capability compared with the parental <i>wt</i>RSV.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1829916. PubMed ID: 42338594. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/evaluation-of-a-strain-long-human-respiratory-syncytial-virus-with-lt-i-829916/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides